Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
Asco 2020 movers – cell therapy companies dominate the risers
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Go or no go? Oncology dominates upcoming decisions
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
Will pending clinical readouts make it across the line?
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.
Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
Pfizer's abrocitinib heads against Dupixent in atopic dermatitis, while Myovant hopes to raise its Spirits.
Relugolix gets a Hero’s welcome in prostate cancer
The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
Sumitomo bets on Roivant to solve its patent expiry woes
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
